<div id="readability-page-1"><p>ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was down 4.5% during mid-day trading on Thursday . The company traded as low as $3.88 and last traded at $3.9050. Approximately 740,786 shares were traded  during trading, an increase of 12% from the average daily volume of 659,677 shares. The stock had previously closed at $4.09.</p><div><p><span></span><span>Get <strong>ADC Therapeutics</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><p>Several equities analysts recently weighed in on ADCT shares. HC Wainwright dropped their price target on shares of ADC Therapeutics from $8.00 to $7.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, October 16th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of ADC Therapeutics in a research note on Wednesday, January 21st. Royal Bank Of Canada  restated an &#34;outperform&#34; rating and issued a $5.00 target price on shares of ADC Therapeutics in a report on Wednesday, December 3rd. Wall Street Zen upgraded ADC Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 15th. Finally, Guggenheim  reissued a &#34;buy&#34; rating and issued a $10.00 price target on shares of ADC Therapeutics in a research report on Wednesday, November 12th. Five equities research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the stock. According to MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $7.50.</p><p><b>Read Our Latest Stock Analysis on ADC Therapeutics</b></p><h2>ADC Therapeutics Stock Down 4.5%</h2><p>The firm has a market cap of $483.74 million, a P/E ratio of -2.69 and a beta of 1.93. The firm's 50-day simple moving average is $3.73 and its 200 day simple moving average is $3.67. </p><p>ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.10. The firm had revenue of $16.43 million for the quarter, compared to the consensus estimate of $17.08 million.  As a group, analysts forecast that  ADC Therapeutics SA will post -1.69 earnings per share for the current year. </p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors and hedge funds have recently bought and sold shares of the business. R Squared Ltd bought a new stake in  ADC Therapeutics during the 3rd quarter valued at $59,000.  Henrickson Nauta Wealth Advisors Inc. bought a new stake in shares of  ADC Therapeutics during the 4th quarter valued at $69,000.  SG Americas Securities LLC purchased a new stake in  ADC Therapeutics during the 4th quarter worth about $86,000.  Creative Planning purchased a new stake in  ADC Therapeutics during the 2nd quarter worth about $96,000.  Finally, Ethic Inc. bought a new position in  ADC Therapeutics in the 2nd quarter worth about $103,000. 41.10% of the stock is owned by institutional investors. </p><h2>About ADC Therapeutics</h2> (Get Free Report)<p>ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.  </p><p>At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than ADC Therapeutics</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>EXPOSED: The “29% Account”</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Missed Nvidia? Your next 12-month window</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ADC Therapeutics Right Now?</h2><p>Before you consider ADC Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADC Therapeutics wasn't on the list.</p><p>While ADC Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>ADC Therapeutics (NYSE:ADCT) stock fell 4.5% to $3.9050 during mid-day trading, with 740,786 shares traded. Analysts have mixed ratings, with HC Wainwright lowering its price target from $8.00 to $7.00 while maintaining a "buy" rating. The company reported a quarterly loss of ($0.30) per share, beating estimates, but revenue was below expectations at $16.43 million. Institutional investors own 41.10% of the stock, and the average price target among analysts is $7.50, indicating a consensus rating of "Moderate Buy."</p>

Market Beat

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

iShares Global Healthcare

iShares Biotechnology ETF

ADC Therapeutics SA

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

iShares US Pharma

VG Health

Proshares Ultra Nasdaq Biotech

ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5%  - Here's Why